Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
21.35
Dollar change
+0.66
Percentage change
3.19
%
IndexRUT P/E9.25 EPS (ttm)2.31 Insider Own9.85% Shs Outstand83.98M Perf Week-10.18%
Market Cap1.80B Forward P/E7.90 EPS next Y2.70 Insider Trans0.00% Shs Float75.96M Perf Month-6.03%
Income197.92M PEG2.98 EPS next Q0.50 Inst Own66.80% Short Float12.12% Perf Quarter-5.11%
Sales492.05M P/S3.66 EPS this Y-0.77% Inst Trans-0.01% Short Ratio5.22 Perf Half Y-45.34%
Book/sh9.38 P/B2.28 EPS next Y5.93% ROA26.25% Short Interest9.21M Perf Year-40.81%
Cash/sh8.80 P/C2.43 EPS next 5Y3.10% ROE29.50% 52W Range18.57 - 48.25 Perf YTD-4.00%
Dividend Est.- P/FCF10.59 EPS past 5Y47.29% ROI24.93% 52W High-55.75% Beta2.16
Dividend TTM- Quick Ratio12.29 Sales past 5Y39.35% Gross Margin83.60% 52W Low14.97% ATR (14)1.13
Dividend Ex-Date- Current Ratio13.18 EPS Y/Y TTM20.94% Oper. Margin39.76% RSI (14)41.05 Volatility5.23% 4.25%
Employees581 Debt/Eq0.01 Sales Y/Y TTM8.32% Profit Margin40.22% Recom2.33 Target Price28.40
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q47.17% Payout0.00% Rel Volume0.88 Prev Close20.69
Sales Surprise1.61% EPS Surprise8.10% Sales Q/Q-5.08% EarningsFeb 13 BMO Avg Volume1.77M Price21.35
SMA20-9.81% SMA50-6.11% SMA200-29.14% Trades Volume1,549,550 Change3.19%
Date Action Analyst Rating Change Price Target Change
Nov-03-23Downgrade UBS Buy → Neutral $52 → $24
Oct-13-23Downgrade Canaccord Genuity Buy → Hold $55 → $22
Mar-29-23Initiated UBS Buy $40
Feb-17-23Downgrade Needham Buy → Hold
Dec-21-22Initiated Barclays Overweight $44
Oct-12-22Initiated Jefferies Buy $40
May-25-21Initiated Barclays Overweight $92
May-18-21Initiated Needham Buy $94
Sep-03-19Initiated UBS Buy $28
Sep-03-19Initiated Robert W. Baird Outperform $27
Today 01:00PM
09:30AM
Feb-22-24 07:12PM
Feb-14-24 09:36AM
02:29AM
06:15PM Loading…
Feb-13-24 06:15PM
02:06PM
08:02AM
07:21AM
07:00AM
Feb-12-24 05:37AM
Feb-05-24 05:50PM
Jan-30-24 05:50PM
Jan-27-24 06:57PM
Jan-24-24 05:50PM
06:00PM Loading…
Jan-23-24 06:00PM
Jan-17-24 06:00PM
Jan-16-24 07:00AM
Jan-08-24 05:50PM
Jan-07-24 08:30AM
Jan-04-24 06:00PM
Dec-29-23 09:30AM
Dec-28-23 06:00PM
Dec-22-23 05:50PM
Dec-15-23 09:00AM
Dec-13-23 07:33AM
Dec-08-23 10:13AM
Dec-06-23 07:00AM
05:40AM
Dec-04-23 09:00AM
08:10AM Loading…
Dec-02-23 08:10AM
Nov-21-23 09:00AM
Nov-09-23 09:00AM
Nov-06-23 08:30AM
Nov-03-23 11:18AM
Nov-02-23 04:00PM
07:52AM
07:00AM
Oct-30-23 10:00AM
Oct-27-23 05:50PM
Oct-26-23 10:02AM
Oct-25-23 09:00AM
Oct-24-23 07:53AM
Oct-20-23 05:50PM
Oct-18-23 09:53AM
Oct-17-23 06:00PM
Oct-13-23 08:00AM
Oct-12-23 08:00AM
Oct-09-23 04:44PM
12:11PM
07:50AM
Oct-02-23 06:00PM
09:00AM
Sep-26-23 06:00PM
Sep-22-23 07:01AM
Sep-20-23 06:00PM
09:00AM
Sep-14-23 06:00PM
Sep-08-23 05:50PM
Sep-06-23 09:00AM
Sep-05-23 08:00AM
Sep-04-23 09:40AM
Sep-03-23 05:29AM
Sep-01-23 05:50PM
Aug-27-23 01:54PM
Aug-23-23 06:15AM
Aug-20-23 04:14PM
Aug-18-23 09:00AM
06:20AM
Aug-17-23 09:40AM
Aug-11-23 08:35AM
Aug-09-23 10:12AM
Aug-01-23 10:06AM
08:00AM
Jul-30-23 05:39AM
Jul-29-23 09:45AM
Jul-28-23 04:45PM
Jul-27-23 05:00PM
08:35AM
07:33AM
07:00AM
Jul-26-23 09:40AM
Jul-25-23 11:46AM
08:00AM
Jul-21-23 05:50PM
Jul-19-23 06:00PM
09:00AM
Jul-18-23 09:10AM
Jul-13-23 06:00PM
Jul-12-23 04:40PM
04:03PM
08:41AM
08:04AM
07:00AM
Jul-10-23 10:00AM
Jul-03-23 02:20PM
Jun-30-23 09:40AM
Jun-26-23 07:59AM
Jun-21-23 08:41PM
Jun-14-23 09:40AM
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.